Libtayo® (cemiplimab) neoadjuvant treatment demonstrates encouraging event-free survival in patients with resectable cutaneous squamous cell carcinoma (cscc)

89% estimated event-free survival at one year among patients with stage ii to iv resectable cscc who received libtayo prior to surgery in a phase 2 trial
REGN Ratings Summary
REGN Quant Ranking